Drug Discovery – EBiSC Distribution

Understanding the role of genetic risk factors in Alzheimer’s disease is critical for developing effective treatments. One of the most important genetic contributors is APOE, with the APOE4 variant significantly increasing disease risk.

To support the research community, EBiSC offers a collection of APOE isogenic iPSC lines. These carefully engineered cell lines differ only at the APOE locus, providing researchers with tools to investigate the specific biological effects of APOE variants while minimising genetic background variability.

Isogenic iPSC cohorts are generated from:
– Male and female backgrounds
– Alzheimer disease affected (APOE4/E4) and unaffected (APOE3/E3 and APOE3/E4) individuals

See more information on available isogenic cohorts here: https://ebisc.org/collections/APOE

We’re excited to announce that CellBank Australia is now the official distributor of the EBiSC stem cell collection for Australia and New Zealand — making it easier than ever for researchers across Oceania to access 950+ high-quality iPSC lines covering more than 45 disease areas, including cardiovascular, neurological, and metabolic disorders.

This partnership expands EBiSC’s global reach, ensuring that our validated iPSC lines and pre-differentiated cells are available to support research in disease modelling, drug discovery, and regenerative medicine across the region.

Operated by the Children’s Medical Research Institute (CMRI), CellBank brings 18+ years of expertise in authenticated cell lines and quality control services. The collaboration is further strengthened by CMRI’s Stem Cell and Organoid Facility, advancing 3D organoid models and translational research.

📧 cellbank@cmri.org.au

🌐 https://www.cellbankaustralia.com/cell-lines-for-distribution/

Tag: Drug Discovery

🧬EBiSC’s APOE isogenic iPSC lines

Big news for biomedical researchers in Australia and New Zealand!